Bristol-Myers Squibb (BMY) 10-K2006 FY Annual report

Filed: 26 Feb 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: acre, Advisor, agitation, ago, Alcon, alter, Americo, Amgen, apixaban, Arca, AstraZeneca, ATRIPLA, Barr, biosimilar, blended, Brazilian, Bulgaria, calibration, Centre, CEO, clause, collusion, Congressional, contemplated, crime, CT, cytotoxic, dacarbazine, dapagliflozin, database, Deloitte, device, digit, disallowance, displayed, disrupt, distributorship, double, EFFERLAGAN, effervescent, eighteen, Eli, endpoint, enjoin, enjoined, enrollment, explanatory, fever, FTR, GLEEVEC, graph, Guidant, Guideline, Helmholtz, holder, Hybrid, hydrochlorothiazide, imatinib, immunoscience, implied, incapable, incompatible, Infektionsforschung, inflationary, input, Interbank, irrevocable, KENALOG, knowingly, Korean, land, learned, leaseback, legacy, Lilly, lock, lodged, LUMINITY, lymphoid, Majeure, Manati, Marchese, meslylate, mesylate, methotrexate, mg, Ministry, misled, misrepresented, Monte, multiemployer, myeloid, myloid, nonvested, NORVIR, NY, NYSE, Oakland, observed, obstruction, Ohio, onRating, operationally, output, overfunded, override, paracetamol, path, pathway, Pfizer, pivotal, placement, pledge, pledged, PMDA, point, pre, precipitously, premium, quantify, quantifying, radiation, rehearing, remeasurement, renminbi, renovate, repayment, resistance, Ritonavir, Romania, Rowan, RxUSA, Sampson, Sandoz, securitized, seller, Sherman, simulation, specialist, SPRYCEL, Starkman, Stephenson, steroid, Sun, Synthon, tabular, taxpayer, TechneLite, technique, thromboembolic, timeframe, Touche, Tribunal, TRICARE, TRIZIVIR, TRx, tyrosine, unlawful, unqualified, UNRESOLVED, untreated, unwind, upheld, variance, Weisz, welfare, wrongly, Zentrum

Removed: accretion, ACE, actuarially, advisory, agonist, Alabama, Anthony, anticompetitive, Arizona, autoimmune, Bodnar, Botanical, Bush, BUSPAR, challenging, close, closed, coated, commerce, compendia, comprise, conflict, Connecticut, consolidate, continent, correct, corrected, declined, deficiency, deliver, deploy, dictated, disproportionate, disseminated, Dixon, downsize, downsizing, EITF, Energy, enteric, essentially, EXCEDRIN, false, falsely, FAS, FTC, grew, Heimbold, Hooper, House, Howson, immune, improperly, indemnify, inside, Intercontinental, involvement, ischemic, Jr, losing, master, McGoldrick, metabolic, metformin, Mississippi, Montana, Nevada, NS, older, overstating, phenylpropanolamine, pioneer, PPA, PPAR, pretrial, profile, promise, published, PwC, readily, recover, reorganization, reorganized, restitution, Ringrose, secondary, separation, setting, settled, sNDA, solution, STADOL, staffing, statin, stretch, subordinated, subpoena, subsidy, sufficiently, Tamar, Treasurer, treble, tubulin, varied, VIDEX, VIE, vitamin, Weizmann, Wendy, West, workdown

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

BMY similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32a.

Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as

Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U. S. C. Section 1350, I, James M. Cornelius, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Annual Report on Form 10-K for the year ended December 31, 2006 (the Report), as filed with the Securities and Exchange Commission on February 26, 2007, fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Bristol-Myers Squibb Company.

/s/ James M. Cornelius

James M. Cornelius

Chief Executive Officer

February 26, 2007

E-32-1